A once-daily pill from drugmaker AstraZeneca cut deaths in half among a subset of early-stage lung cancer patients who had undergone surgery, according to new clinical trial results.
The data is the first to show how a targeted treatment for early-stage lung cancer impacts survival, said Dr. Roy Herbst, the trial's principal investigator and deputy director at Yale Cancer Center. The drug, called osimertinib and sold under the name Tagrisso, is directed at a specific receptor that helps cancer cells grow.
The trial included people with stages 1, 2 and 3 non-small cell lung cancer, the most common type of lung cancer. Patrick Forde, an associate oncology professor at Johns Hopkins Medicine, said that before targeted treatments like Tagrisso were available, patients with stage 1 to 3 lung cancer would normally receive chemotherapy after surgery. That might improve their odds of survival by about about 5% compared to those who didn't receive chemo, he estimated.
One lingering question, Forde said, is whether survival rates would stay the same if patients were given the pill after their cancer relapsed versus immediately after surgery. However, doctors generally recognize that treating cancer early improves survival rates.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patientsAstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically removed, trial data showed.
Baca lebih lajut »
Tiny valves making a big difference for emphysema patients at Temple Lung CenterIt's been five years since the FDA approved the first valves to treat severe emphysema. And since then, they've turned life around for patients.
Baca lebih lajut »
Lung cancer pill drastically cuts risk of death after surgeryTaking the drug Tagrisso daily after surgery reduced non-small cell lung cancer patients' death risk by more than 50%.
Baca lebih lajut »
Lung cancer pill found to reduce risk of death after surgery by halfOsimertinib, specially developed to treat the most common type of lung cancer called non-small cell lung cancer, showed promise in 88 percent of patients.
Baca lebih lajut »
Lung Cancer Pill Cuts Risk of Dying by Half in Major TrialAstraZeneca's osimertinib, in combination with surgery, substantially improved the long-term survival of patients with a common form of lung cancer.
Baca lebih lajut »
This Pill Can Halve The Risk of Death After Lung Cancer, Scientists SayA pill has been shown to halve the risk of death from a certain type of lung cancer when taken daily after surgery to remove the tumor, according to clinical trial results presented on Sunday.
Baca lebih lajut »